Table 2. Trends in thymic cancer age standardized rate by histologic types, sex, races in USCS, United States, 2001–2015.
| Incidence | Trend 1 | Trend 2 | 2001–2015 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 2001 | 2015 | Years | APC | 95% CI | Years | APC | 95% CI | AAPC | |
| All histologic Types, both sexes, all races | 0.23 | 0.30 | 2001–2006 | 4.9* | 1.8–8.1 | 2006–2015 | 0.1 | -1.0–1.2 | 1.8* |
| Thymoma | 0.16 | 0.19 | 2001–2008 | 2.9* | 1.8–4.0 | 2008–2015 | -0.9 | -1.9–0.0 | 1.0* |
| Thymic carcinoma | 0.03 | 0.07 | 2001–2004 | 15.7 | -2.1–36.7 | 2004–2015 | 2.6* | 1.0–4.3 | 5.3* |
| Thymic neuroendocrine tumor | 0.01 | 0.01 | 2001–2015 | -2.3 | -4.7–0.2 | -2.3 | |||
| Sex | |||||||||
| Male | 0.28 | 0.35 | 2001–2015 | 1.0* | 0.1–2.0 | 1.0* | |||
| Female | 0.18 | 0.26 | 2001–2009 | 4.0* | 1.9–6.2 | 2009–2015 | -1.3 | -3.9–1.5 | 1.7* |
| Race | |||||||||
| White | 0.21 | 0.25 | 2001–2005 | 5.8* | 0.8–11.1 | 2005–2015 | -0.3 | -1.4–0.8 | 1.4 |
| Black | 0.33 | 0.50 | 2001–2015 | 2.0* | 0.9–3.1 | 2.0* | |||
| Asian/Pacific Islander | 0.37 | 0.60 | 2001–2015 | 2.4* | 0.2–4.6 | 2.4* | |||
| Male | |||||||||
| Thymoma | 0.19 | 0.21 | 2001–2015 | 0.4 | -0.5–1.3 | 0.4 | |||
| Thymic carcinoma | 0.04 | 0.10 | 2001–2015 | 4.1* | 2.5–5.8 | 4.1* | |||
| Thymic neuroendocrine tumor | 0.02 | 0.01 | 2001–2015 | -2.9* | -5.1 - -0.6 | -2.9* | |||
| Female | |||||||||
| Thymoma | 0.14 | 0.18 | 2001–2012 | 2.5* | 1.5–3.6 | 2012–2015 | -5.4 | -11.9–1.6 | 0.8 |
| Thymic carcinoma | 0.02 | 0.05 | 2001–2009 | 7.9* | 3.0–13.0 | 2009–2015 | -1.7 | -6.9–3.7 | 3.7* |
| Thymic neuroendocrine tumor | - | - | - | - | - | - | |||
Abbreviation: CI, confidence interval; AAPC, average annual percent change over the most recent data years; APC, annual percent change
*The APC or AAPC is significantly different from zero (P < .05).